AR053440A2 - Uso de una forma de dosificacion farmaceutica de liberacion sostenida para la manufactura de un medicamento, dicha forma de dosificacion farmaceutica y una tableta comprimida - Google Patents

Uso de una forma de dosificacion farmaceutica de liberacion sostenida para la manufactura de un medicamento, dicha forma de dosificacion farmaceutica y una tableta comprimida

Info

Publication number
AR053440A2
AR053440A2 ARP060100699A ARP060100699A AR053440A2 AR 053440 A2 AR053440 A2 AR 053440A2 AR P060100699 A ARP060100699 A AR P060100699A AR P060100699 A ARP060100699 A AR P060100699A AR 053440 A2 AR053440 A2 AR 053440A2
Authority
AR
Argentina
Prior art keywords
dosage form
pharmaceutical dosage
phthalate
manufacture
medicinal product
Prior art date
Application number
ARP060100699A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053440(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc, Syntex Inc filed Critical Cv Therapeutics Inc
Publication of AR053440A2 publication Critical patent/AR053440A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

El uso de ranolazina y por lo menos un aglutinante dependiente del pH seleccionado entre copolímeros de ácido metacrilato, hidroxipropil celulosa ftalato, hidroxipropil metilcelulosa ftalato, celulosa acetato ftalato, polivinil acetato ftalato, polivinilpirrolidina ftalato y mezclas de los mismos, que es para la preparacion de una composicion farmacéutica de liberacion sostenida para tratar a un humano que sufre de una enfermedad cardiovascular seleccionada de arritmias, angina variante e inducida por ejercicio e infarto de miocardio, o claudicacion intermitente donde la composicion farmacéutica es para administracion una o dos veces al día.
ARP060100699A 1998-09-10 2006-02-24 Uso de una forma de dosificacion farmaceutica de liberacion sostenida para la manufactura de un medicamento, dicha forma de dosificacion farmaceutica y una tableta comprimida AR053440A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation

Publications (1)

Publication Number Publication Date
AR053440A2 true AR053440A2 (es) 2007-05-09

Family

ID=26796494

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990104545A AR022085A1 (es) 1998-09-10 1999-09-09 Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
ARP060100700A AR052921A1 (es) 1998-09-10 2006-02-24 Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
ARP060100699A AR053440A2 (es) 1998-09-10 2006-02-24 Uso de una forma de dosificacion farmaceutica de liberacion sostenida para la manufactura de un medicamento, dicha forma de dosificacion farmaceutica y una tableta comprimida

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP990104545A AR022085A1 (es) 1998-09-10 1999-09-09 Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
ARP060100700A AR052921A1 (es) 1998-09-10 2006-02-24 Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica

Country Status (33)

Country Link
US (14) US6303607B1 (es)
EP (3) EP1096937B9 (es)
JP (2) JP3745621B2 (es)
KR (1) KR100475759B1 (es)
CN (2) CN1193757C (es)
AR (3) AR022085A1 (es)
AT (2) ATE217794T1 (es)
AU (4) AU760435B2 (es)
BR (2) BR9913553A (es)
CA (2) CA2343376C (es)
CY (1) CY2008020I1 (es)
CZ (2) CZ301375B6 (es)
DE (3) DE69901570T2 (es)
DK (2) DK1096937T3 (es)
ES (2) ES2234302T3 (es)
FR (1) FR09C0001I2 (es)
GE (1) GEP20053420B (es)
HK (2) HK1040060A1 (es)
HU (2) HU224215B1 (es)
IL (6) IL141893A0 (es)
LU (1) LU91504I2 (es)
MX (2) MXPA01002599A (es)
NL (1) NL300371I2 (es)
NO (4) NO320986B1 (es)
NZ (2) NZ510386A (es)
PL (3) PL196263B1 (es)
PT (2) PT1096937E (es)
RU (2) RU2207856C2 (es)
SI (2) SI1096937T1 (es)
TR (2) TR200101262T2 (es)
TW (1) TWI241911B (es)
UA (2) UA67793C2 (es)
WO (2) WO2000013687A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6528511B2 (en) 2000-02-18 2003-03-04 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
ATE407674T1 (de) * 2002-04-09 2008-09-15 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
IL165304A0 (en) * 2002-05-21 2006-01-15 Cv Therapeutics Inc Method of treating diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
US20060177502A1 (en) * 2005-01-06 2006-08-10 Srikonda Sastry Sustained release pharmaceutical formulations
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2007016350A2 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
EP1998387B1 (en) * 2006-03-17 2015-04-22 Konica Minolta Holdings, Inc. Organic electroluminescent device, display and illuminating device
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
JP2010518181A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
ATE509015T1 (de) * 2007-03-07 2011-05-15 Concert Pharmaceuticals Inc Deuterierte piperazinderivate als verbindungen gegen angina
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EP2170333B1 (en) * 2007-05-31 2013-02-20 Gilead Sciences, Inc. Ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
AU2008266124A1 (en) * 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (es) 2011-07-01 2018-04-28
AU2012312266A1 (en) 2011-09-21 2013-05-02 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
US20160305924A1 (en) * 2013-04-26 2016-10-20 Laguna Pharmaceuticals , Inc. Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
NZ234184A (en) * 1989-06-23 1997-01-29 Syntex Pharma Ltd Treating tissues with a ranolazine derivative
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine

Also Published As

Publication number Publication date
EP1096937B1 (en) 2004-12-29
IL141893A (en) 2008-08-07
HUP0103844A2 (hu) 2002-04-29
AU6036499A (en) 2000-03-27
LU91504I2 (fr) 2009-02-03
US6864258B2 (en) 2005-03-08
DK1096937T3 (da) 2005-05-09
DE69901570D1 (de) 2002-06-27
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
IL141892A0 (en) 2002-03-10
US20060217397A1 (en) 2006-09-28
NL300371I2 (nl) 2009-10-01
DK1109558T3 (da) 2002-08-26
AU760435B2 (en) 2003-05-15
ATE285774T1 (de) 2005-01-15
US20030100566A1 (en) 2003-05-29
NO20011191L (no) 2001-04-30
CZ301341B6 (cs) 2010-01-20
HU224215B1 (hu) 2005-06-28
UA67793C2 (uk) 2004-07-15
NO20011192L (no) 2001-04-30
AR022085A1 (es) 2002-09-04
HK1044284A1 (en) 2002-10-18
US20060147521A1 (en) 2006-07-06
US20030166659A1 (en) 2003-09-04
WO2000013687A2 (en) 2000-03-16
NO20011192D0 (no) 2001-03-08
RU2207856C2 (ru) 2003-07-10
CN1354665A (zh) 2002-06-19
US6562826B1 (en) 2003-05-13
NO20011191D0 (no) 2001-03-08
UA75027C2 (uk) 2006-03-15
ES2234302T3 (es) 2005-06-16
HK1044284B (zh) 2005-07-15
CA2342390A1 (en) 2000-03-16
BR9913626A (pt) 2001-12-04
GEP20053420B (en) 2005-01-25
FR09C0001I2 (es) 2009-12-18
PL202207B1 (pl) 2009-06-30
CZ2001879A3 (cs) 2001-08-15
NO2009005I2 (es) 2010-06-28
PL348249A1 (en) 2002-05-20
PL196263B1 (pl) 2007-12-31
US20020090396A1 (en) 2002-07-11
JP2006096757A (ja) 2006-04-13
PT1096937E (pt) 2005-04-29
NZ510386A (en) 2003-08-29
CY2008020I2 (el) 2010-07-28
WO2000013687A3 (en) 2000-06-29
TR200101262T2 (tr) 2001-12-21
CA2343376C (en) 2007-01-09
EP1527779A1 (en) 2005-05-04
HUP0103844A3 (en) 2002-11-28
US6525057B2 (en) 2003-02-25
CN1193757C (zh) 2005-03-23
ES2177346T3 (es) 2002-12-01
US6620814B2 (en) 2003-09-16
HUP0104088A3 (en) 2002-12-28
BR9913553A (pt) 2001-10-23
DE122008000065I1 (de) 2009-04-09
CN1211086C (zh) 2005-07-20
HK1040060A1 (en) 2002-05-24
US20040029890A1 (en) 2004-02-12
NZ510384A (en) 2002-10-25
IL141892A (en) 2006-08-20
CN1321088A (zh) 2001-11-07
TR200101261T2 (tr) 2002-05-21
KR100475759B1 (ko) 2005-03-10
NO20054324L (no) 2001-04-30
CA2343376A1 (en) 2000-03-16
CA2342390C (en) 2006-08-29
AU744071B2 (en) 2002-02-14
MXPA01002598A (es) 2002-04-08
RU2214233C2 (ru) 2003-10-20
LU91504I9 (es) 2019-01-02
ATE217794T1 (de) 2002-06-15
US20050153982A1 (en) 2005-07-14
US6852724B2 (en) 2005-02-08
CY2008020I1 (el) 2010-07-28
NO319434B1 (no) 2005-08-15
DE69901570T2 (de) 2003-01-09
PT1109558E (pt) 2002-10-31
NO2009005I1 (no) 2009-03-16
US20040097514A1 (en) 2004-05-20
IL180864A0 (en) 2007-07-04
EP1096937A2 (en) 2001-05-09
IL175371A0 (en) 2006-09-05
JP2002524416A (ja) 2002-08-06
AR052921A1 (es) 2007-04-11
EP1109558A2 (en) 2001-06-27
DE69922964D1 (de) 2005-02-03
EP1109558B1 (en) 2002-05-22
US20020004506A1 (en) 2002-01-10
HUP0104088A2 (hu) 2002-05-29
DE69922964T2 (de) 2005-12-08
KR20010089874A (ko) 2001-10-12
US20030099705A1 (en) 2003-05-29
TWI241911B (en) 2005-10-21
MXPA01002599A (es) 2005-02-17
JP3745621B2 (ja) 2006-02-15
US6617328B2 (en) 2003-09-09
SI1109558T1 (en) 2002-10-31
AU2008207703A1 (en) 2008-09-25
SI1096937T1 (en) 2005-04-30
NO320986B1 (no) 2006-02-20
NL300371I1 (nl) 2009-02-02
US20050059667A1 (en) 2005-03-17
FR09C0001I1 (es) 2009-02-27
PL196668B1 (pl) 2008-01-31
AU2008207707A1 (en) 2008-09-25
IL141893A0 (en) 2002-03-10
CZ301375B6 (cs) 2010-02-03
US6503911B2 (en) 2003-01-07
US6369062B1 (en) 2002-04-09
WO2000013686A3 (en) 2000-07-06
CZ2001880A3 (cs) 2001-08-15
AU6142599A (en) 2000-03-27
EP1096937B9 (en) 2007-02-28
US6303607B1 (en) 2001-10-16

Similar Documents

Publication Publication Date Title
AR053440A2 (es) Uso de una forma de dosificacion farmaceutica de liberacion sostenida para la manufactura de un medicamento, dicha forma de dosificacion farmaceutica y una tableta comprimida
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
ES2181417T3 (es) Formulacion de capsulas o tabletas de efavirenz de disolucion rapida usando super-desintegrantes.
AR026745A1 (es) Composiciones de eplerenona nanoparticulada
UY24875A1 (es) Composiciones farmacéuticas conteniendo tetrahidrolipstatina
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
AR005282A1 (es) Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura.
HUP0203257A2 (hu) Atorvastatin kalcium polimorf módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
AR024384A1 (es) UNA FORMA DE DOSIFICACIoN FARMACÉUTICA DE DISOLUCIoN INSTANTÁNEA Y UN MÉTODO PARA PREPARARLA
ES555899A0 (es) Un procedimiento para preparar una composicion farmaceutica oral, de accion prolongada, en forma de dosificacion unitaria solida.
EA200000245A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
IT1276689B1 (it) Forma farmaceutica solida ad uso orale
AR036658A1 (es) Formulacion de dosificacion oral de fundicion instantanea
HUP0401569A2 (hu) Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
AR029312A1 (es) Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh, procesos para su produccion, formulacion farmaceutica, y uso de estos compuestos para la elaboracion de un medicamento.
ES2176106B1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
RU2005137031A (ru) Фармацевтическая композиция с натриевой солью телмисартана
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
BR9807992A (pt) Comprimidos para engolir os quais compreendem paracetamol
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
HUP0204202A2 (hu) Ibuprofent tartalmazó hatóanyag-preparátum, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
SE8901003D0 (sv) Snabbloesliga preparat
SE9003904D0 (sv) Method for the manufacture of a pharmaceutical dosage form

Legal Events

Date Code Title Description
FA Abandonment or withdrawal